News
IRWD
4.130
-1.43%
-0.060
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
NASDAQ · 4d ago
Weekly Report: what happened at IRWD last week (0914-0918)?
Weekly Report · 4d ago
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
NASDAQ · 09/14 13:30
Weekly Report: what happened at IRWD last week (0907-0911)?
Weekly Report · 09/14 09:55
Ironwood: Medicare Is Not The Problem I Thought It Was
Seeking Alpha · 09/11 13:42
Weekly Report: what happened at IRWD last week (0831-0904)?
Weekly Report · 09/07 09:51
Weekly Report: what happened at IRWD last week (0824-0828)?
Weekly Report · 08/31 09:56
Ironwood Pharmaceuticals: High Dependence On Its Next Trial
Seeking Alpha · 08/26 17:10
Weekly Report: what happened at IRWD last week (0817-0821)?
Weekly Report · 08/24 09:56
Weekly Report: what happened at IRWD last week (0810-0814)?
Weekly Report · 08/17 09:57
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/13 17:43
Weekly Report: what happened at IRWD last week (0803-0807)?
Weekly Report · 08/10 09:53
Ironwood Pharmaceuticals (IRWD) Stock Faces A Sentiment Check After Raised Guidance
Simply Wall St · 08/07 23:44
Ironwood Pharmaceuticals’ Earnings Call Highlights LINZESS Surge
TipRanks · 08/07 00:20
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
NASDAQ · 08/06 20:04
*Ironwood Pharmaceuticals Raises FY26 View To Rev $460M-$485M >IRWD
Dow Jones · 08/06 11:21
Ironwood Pharmaceuticals reports mixed Q2 results; raises FY26 outlook
Seeking Alpha · 08/06 11:20
*Ironwood Pharmaceuticals Raises 2026 Full-Yr Fincl Guidance
Dow Jones · 08/06 11:19
*Ironwood Pharmaceuticals 2Q Net $51.3M >IRWD
Dow Jones · 08/06 11:05
*Ironwood Pharmaceuticals 2Q EPS 31c >IRWD
Dow Jones · 08/06 11:05
More
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.